Strata Oncology Announces Personalized Recurrence Monitoring Trial

"The Sentinel Trial will support the validation of our personalized recurrence monitoring assay for patients with solid tumors in a diverse population," said Dan Rhodes , PhD, co-founder and Chief Executive Officer, Strata Oncology.